Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
guanoxan
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Guanoxan is a small molecule antihypertensive agent that was used for the treatment of hypertension. Its mechanism of action involves blocking alpha-2 adrenergic receptors (adrenoceptors), which inhibits the release of norepinephrine—a neurotransmitter that promotes vasoconstriction and increases blood pressure. By reducing norepinephrine release, guanoxan lowers both systolic and diastolic blood pressure in both lying and standing positions. Guanoxan is structurally classified as a benzo-1,4-dioxane derivative. The drug was approved in the UK but was withdrawn from the market due to hepatotoxicity (liver damage)[1][2][3][5][7].
- Other names
- guanoxanoguanoxanumguanoxane2-guanidinomethylbenzo-1,4-dioxan
02
Targets
ADRA2A (α2A)
Beyond the preview
Go deeper on guanoxan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on guanoxan.